by Lance Smith | Jan 30, 2020 | Study Scavenger Clinical Trial Recruitment Platform
Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that it has begun dosing healthy volunteers in a Phase 1 clinical trial of CVL-936, an orally-administered and potential first-in-class...by Lance Smith | Jan 30, 2020 | Study Scavenger Clinical Trial Recruitment Platform
Clinical Data Intended to be Used to Support Pediatric Label Expansion for IXINITY Approximately 1/3 of U.S. Hemophilia B Patients are Under Twelve Years of Age; Pediatric Approval Could Significantly Increase the Addressable Patient Population for IXINITY SEATTLE, WA...by Lance Smith | Jan 30, 2020 | Study Scavenger Clinical Trial Recruitment Platform
CAMBRIDGE, Mass., Jan. 30, 2020 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the...by Lance Smith | Jan 29, 2020 | Study Scavenger Clinical Trial Recruitment Platform
JoBurmester.com is delighted to announce the launch of the first in a series of online learning courses designed to make clinical research regulatory training as effective as possible. Written by Jo Burmester, a well known expert in Good Clinical Practice (GCP), this...by Lance Smith | Jan 29, 2020 | Study Scavenger Clinical Trial Recruitment Platform
MELBOURNE, Australia–(Business Wire)–Regenerative medicine company Exopharm Limited (ASX:EX1) announces first dosing has occurred in the PLEXOVAL Phase I study using exosomes isolated from human platelets for wound healing, Exopharm’s first human clinical...by Lance Smith | Jan 29, 2020 | Study Scavenger Clinical Trial Recruitment Platform
CAMBRIDGE, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) — Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced it has completed Cohort 1 enrollment with no...